Figure 2.
The possible predictive biomarkers for TNBC patients treated with platinum-based chemotherapy based on clinical trials. BRCA mutation status and methylation status are the important potential biomarkers for platinum therapy. Based on genome-wide effects, BRCA-likeCGH classifier may identify the functional loss of BRCA and then work as the predictor. HRD score≥ 42 is related to the chemosensitivity to platinum. Besides, high TILs level seems to be associated with better platinum response. p53 family and molecular subtype are also important alternative considerations. Tp, CTC and ctDNA are emerging biomarkers. TIL: Tumor infiltrating lymphocyte; Tp: thrombocytopenia; CTC: circulating tumor cell; ctDNA: circulating tumor DNA.